28. Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine

  1. W. John W. Morrow PhD, DSc, FRCPath4,
  2. Nadeem A. Sheikh PhD5,
  3. Clint S. Schmidt PhD6 and
  4. D. Huw Davies PhD7
  1. Sylvia Janetzki MD1,
  2. Pedro Romero2,
  3. Mario Roederer PhD3,
  4. Diane L. Bolton3 and
  5. Camilla Jandus MD, PhD2

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch28

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

How to Cite

Janetzki, S., Romero, P., Roederer, M., Bolton, D. L. and Jandus, C. (2012) Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch28

Editor Information

  1. 4

    Seattle, WA, USA

  2. 5

    Dendreon Corporation, Seattle, WA, USA

  3. 6

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 7

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. 1

    Zellnet Consulting, Inc., Fort Lee, NJ, USA

  2. 2

    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland

  3. 3

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313

SEARCH

Keywords:

  • immune monitoring;
  • immunotherapeutic and preventive vaccines;
  • bioassays;
  • T cell assays;
  • immune responses;
  • sample logistics

Summary

Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response, whereas preventive vaccination is intended to prevent the development of diseases in healthy subjects. Most successful prophylactic vaccines rely on the induction of high titers of neutralizing antibodies. It is generally thought that therapeutic vaccination requires induction of robust T-cell mediated immunity. The diverse array of potential or already in use immunotherapeutic and preventive agents all share the commonality of stimulating the immune system. Hence, measuring those vaccination-induced immune responses gives the earliest indication of vaccine take and its immune modulating effects.